Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2019

30.08.2019 | Review

Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis

verfasst von: Chao Li, Hongwei Fan, Qian Xiang, Ling Xu, Zhuo Zhang, Qianxin Liu, Tongtong Zhang, Jinjie Ling, Ying Zhou, Xia Zhao, Yimin Cui

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Biomarkers of breast cancer such as hormone receptors (HR) and human epidermal growth factor 2 (HER2) can be altered after neoadjuvant chemotherapy (NAC). However, whether the conversion of these receptors affects the prognosis of patients remains to be determined. We sought to evaluate the prognostic value of HR and HER2 receptors before and after NAC and to analyze their clinical implications. Relevant studies were used to calculate the pooled hazard ratios, 95% confidence interval (95% CI). This meta-analysis included eight studies with 2847 patients. Compared to patients with HR+ → +, patients with HR+ → − have shorter disease free survival (DFS) (hazard ratio = 2.64, 95% CI 1.86–3.75) and overall survival (OS) (hazard ratio = 2.99, 95% CI 1.97–4.54). Furthermore, patients with HR− → + tend to achieve better DFS (hazard ratio = 0.83, 95% CI 0.60–1.17) compared to patients with HR− → −. Patients with HR− → + gain better OS (hazard ratio = 0.67, 95% CI 0.46–0.99) compared to patients exhibiting HR− → −. When comparing patients with HER2+ → − to patients with HER2+ → +, patients with HER2+ → − tended to achieve better DFS (hazard ratio = 1.65, 95% CI 1.08–2.53) though results for OS (hazard ratio = 1.16, 95% CI 0.54–2.49) were not statistically significant. Our data strongly support the need for redetection of HR and HER2 receptor status of surgical sample following neoadjuvant therapy. Changes in HR status induced by NAC can be used as a prognostic factor in breast cancer patients for predicting both OS and DFS. HER2 change may also be valuable for predicting prognosis. Further research should explore therapeutic strategies for those presenting receptor status conversion.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 16(8):2672–2685CrossRef Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 16(8):2672–2685CrossRef
2.
Zurück zum Zitat Mauri D, Pavlidis N, Ioannidis JPA (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. Breast Dis A Year Book Q 97(3):188–194 Mauri D, Pavlidis N, Ioannidis JPA (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. Breast Dis A Year Book Q 97(3):188–194
3.
Zurück zum Zitat Von MG, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol 30(30):1796–1804 Von MG, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol 30(30):1796–1804
4.
Zurück zum Zitat Kong X, Moran MS, Zhang N et al (2011) Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 47(14):2084–2090CrossRef Kong X, Moran MS, Zhang N et al (2011) Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 47(14):2084–2090CrossRef
5.
Zurück zum Zitat Houssami N, Macaskill P, Minckwitz GV et al (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48(18):3342–3354CrossRef Houssami N, Macaskill P, Minckwitz GV et al (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48(18):3342–3354CrossRef
6.
Zurück zum Zitat Morris DM, Edwards J, Gelder F (1991) Hormonal receptors in locally advanced breast cancer: change with response to neoadjuvant chemotherapy? J Surg Oncol 46(3):156–158CrossRef Morris DM, Edwards J, Gelder F (1991) Hormonal receptors in locally advanced breast cancer: change with response to neoadjuvant chemotherapy? J Surg Oncol 46(3):156–158CrossRef
7.
Zurück zum Zitat Hirata T, Shimizu C, Yonemori K et al (2009) Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 101(9):1529–1536CrossRef Hirata T, Shimizu C, Yonemori K et al (2009) Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 101(9):1529–1536CrossRef
8.
Zurück zum Zitat Neubauer H, Gall C, Vogel U et al (2008) Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 28(3B):1797PubMed Neubauer H, Gall C, Vogel U et al (2008) Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 28(3B):1797PubMed
9.
Zurück zum Zitat Ven SVD, Smit VTHBM, Dekker TJA et al (2011) Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 37(6):422–430PubMed Ven SVD, Smit VTHBM, Dekker TJA et al (2011) Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 37(6):422–430PubMed
10.
Zurück zum Zitat Zhang N, Moran MS, Huo Q et al (2011) The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest 29(9):594CrossRef Zhang N, Moran MS, Huo Q et al (2011) The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest 29(9):594CrossRef
11.
Zurück zum Zitat Niikura N, Liu J, Hayashi N et al (2011) Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30(6):593–599CrossRef Niikura N, Liu J, Hayashi N et al (2011) Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30(6):593–599CrossRef
12.
Zurück zum Zitat Jin X, Jiang YZ, Chen S et al (2015) Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. Oncotarget 6(11):9600–9611CrossRef Jin X, Jiang YZ, Chen S et al (2015) Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. Oncotarget 6(11):9600–9611CrossRef
13.
Zurück zum Zitat Tacca O, Penault-Llorca F, Abrial C et al (2007) Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 12(6):636–643CrossRef Tacca O, Penault-Llorca F, Abrial C et al (2007) Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 12(6):636–643CrossRef
14.
Zurück zum Zitat Wang RX, Chen S, Jin X et al (2016) Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. Breast Cancer Res Treat 161:1–9 Wang RX, Chen S, Jin X et al (2016) Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. Breast Cancer Res Treat 161:1–9
15.
Zurück zum Zitat Guarneri V, Dieci MV, Barbieri E et al (2013) Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol 24(12):2990–2994CrossRef Guarneri V, Dieci MV, Barbieri E et al (2013) Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol 24(12):2990–2994CrossRef
16.
Zurück zum Zitat Stroup DF, Berlin JA, Morton SC et al (2008) Meta-analysis of observational studies in epidemiology: a proposal for reporting. J Am Med Assoc 283(15):2008–2012CrossRef Stroup DF, Berlin JA, Morton SC et al (2008) Meta-analysis of observational studies in epidemiology: a proposal for reporting. J Am Med Assoc 283(15):2008–2012CrossRef
17.
Zurück zum Zitat Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(1):16CrossRef Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(1):16CrossRef
18.
Zurück zum Zitat Tan QX, Qin QH, Yang WP et al (2014) Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients. Int J Clin Exp Pathol 7(7):4 Tan QX, Qin QH, Yang WP et al (2014) Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients. Int J Clin Exp Pathol 7(7):4
19.
Zurück zum Zitat Lim SK, Lee MH, Park IH et al (2015) Impact of molecular subtype conversion of breast cancers after neoadjuvant chemotherapy on clinical outcome. Cancer Res Treat 48(1):133–141CrossRef Lim SK, Lee MH, Park IH et al (2015) Impact of molecular subtype conversion of breast cancers after neoadjuvant chemotherapy on clinical outcome. Cancer Res Treat 48(1):133–141CrossRef
20.
Zurück zum Zitat Niikura N, Tomotaki A, Miyata H et al (2015) Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the, Japanese breast cancer registry. Ann Oncol Off J Eur Soc Med Oncol 27(3):480CrossRef Niikura N, Tomotaki A, Miyata H et al (2015) Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the, Japanese breast cancer registry. Ann Oncol Off J Eur Soc Med Oncol 27(3):480CrossRef
21.
Zurück zum Zitat Mittendorf EA, Wu Y, Scaltriti M et al (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381–7388CrossRef Mittendorf EA, Wu Y, Scaltriti M et al (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381–7388CrossRef
22.
Zurück zum Zitat Yoshida A, Hayashi N, Suzuki K et al (2017) Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. Surg Oncol 116(8):1021–1028CrossRef Yoshida A, Hayashi N, Suzuki K et al (2017) Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. Surg Oncol 116(8):1021–1028CrossRef
23.
Zurück zum Zitat Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013CrossRef Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013CrossRef
24.
Zurück zum Zitat Wu JY, Chen WG, Chen XS et al (2014) Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy. Mol Clin Oncol 2(6):997–1002CrossRef Wu JY, Chen WG, Chen XS et al (2014) Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy. Mol Clin Oncol 2(6):997–1002CrossRef
25.
Zurück zum Zitat Lower EE, Khan S, Kennedy D et al (2017) Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer Targets Therapy 9:515–520CrossRef Lower EE, Khan S, Kennedy D et al (2017) Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer Targets Therapy 9:515–520CrossRef
26.
Zurück zum Zitat Lindström LS, Karlsson E, Wilking UM et al (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol Off J Am Soc Clin Oncol 30(21):2601–2608CrossRef Lindström LS, Karlsson E, Wilking UM et al (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol Off J Am Soc Clin Oncol 30(21):2601–2608CrossRef
27.
Zurück zum Zitat Zardavas D, Irrthum A, Swanton C et al (2015) Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 12(7):381–394CrossRef Zardavas D, Irrthum A, Swanton C et al (2015) Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 12(7):381–394CrossRef
28.
Zurück zum Zitat Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953–1958CrossRef Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953–1958CrossRef
29.
Zurück zum Zitat Sidoni A, Scheibel M, Bellezza G (2005) Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett 218(1):117–121CrossRef Sidoni A, Scheibel M, Bellezza G (2005) Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett 218(1):117–121CrossRef
30.
Zurück zum Zitat Juo YY, Johnston FM, Zhang DY et al (2014) Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol 25(12):2314–2327CrossRef Juo YY, Johnston FM, Zhang DY et al (2014) Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol 25(12):2314–2327CrossRef
Metadaten
Titel
Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis
verfasst von
Chao Li
Hongwei Fan
Qian Xiang
Ling Xu
Zhuo Zhang
Qianxin Liu
Tongtong Zhang
Jinjie Ling
Ying Zhou
Xia Zhao
Yimin Cui
Publikationsdatum
30.08.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05421-7

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.